Natco Pharma has initiated Phase-III clinical trial of Molnupiravir capsules in India. Its first patient was dosed at Yashoda Hospitals, Hyderabad.
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within five days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir Capsules in mild COVID-19 patients. NATCO’s clinical trial is planned in 32 hospitals across India. A few established hospitals locally include Yashoda Hospitals, Gleneagles Global Hospitals, KIMS Hospital in Secunderabad and Vizag, and Excel Hospital, where the trial is being conducted.